Published in Vaccine Weekly, March 21st, 2001
L. Corey and colleagues at the Fred Hutchinson Cancer Research Center in Seattle evaluated the efficacy of a vaccine made up of a recombinant gp120 protein delivered via a canarypox vector containing the HIV proteins Gag, Env, and Pro.
They found that their vaccine elicited both memory T-cell and HIV specific antibody responses in a majority of the volunteers. More than six out of 10 (62%) of the study participants showed CD8+ T-cell responses, study data showed, while over 90% developed HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly